Судафед

Quick links to important sections

Судафед

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Судафед

Property Description
Active Ingredients Guaifenesin, Pseudoephedrine
Form Oral tablet, extended-release tablet, capsule, liquid solution
Pharmacological Class Expectorant and Nasal Decongestant Combination
Common Use Relief of congestion (nasal/chest) and mucus build-up
Origin Largely synthetic organic compounds

What Type of Medicine is Судафед and What is it Made Of?

Судафед is classified as an Upper Respiratory Combination drug, designed to address multiple acute cold or allergy symptoms simultaneously. The preparation is a fixed-dose association combining two distinct active ingredients: Guaifenesin and Pseudoephedrine (INN), typically present as the hydrochloride salt. This pairing is one of the most clinically recognized combinations for multi-symptom respiratory relief.

The drug's composition dictates its classification as an Expectorant and Nasal Decongestant Combination. Pseudoephedrine is recognized as a Sympathomimetic Agent that induces vasoconstriction in the nasal lining to reduce swelling and congestion. Guaifenesin, conversely, functions as an expectorant. While Pseudoephedrine is related to an alkaloid found in the Ephedra plant, the substances utilized in modern pharmaceutical preparations are primarily produced through synthetic processes to ensure consistency and purity.

Oral Forms and General Therapeutic Purpose

The preparation is formulated for oral administration and is available in several dosage forms, including standard oral tablets, capsules, and liquid solutions. This combination often includes extended-release variations, which are a distinguishing feature designed to maintain a sustained therapeutic effect over a prolonged duration.

The overarching general therapeutic purpose of this combination is to provide dual-action relief from key respiratory discomforts. This is typically used to alleviate symptoms experienced during a common cold, such as severe nasal congestion and the accumulation of thick, difficult-to-clear mucus. The expectorant makes coughs more effective in clearing phlegm from the respiratory tract.

Regulatory References

  1. National Library of Medicine

What side effects are possible with Судафед?

Possible side effects and safety information

The regulatory safety profile for the Guaifenesin and Pseudoephedrine combination is documented by health authorities, defining both common expected effects and potential rare, serious adverse reactions.

Adverse Reaction Scope

The most frequent effects are generally related to the stimulating properties of pseudoephedrine, primarily affecting the central nervous system and the cardiovascular system. Adverse reactions are classified by frequency in official labeling:

  • Very Common: Headache.
  • Common: Insomnia, Nervousness, Dry Mouth, Nausea.
  • Not Known: This category includes effects for which frequency cannot be accurately estimated from available data, such as anxiety, palpitations, tachycardia, hypertension, vomiting, and urinary retention. Also classified as Not Known are rare, serious events like Myocardial infarction and certain severe skin reactions (e.g., Acute Generalized Exanthematous Pustulosis or AGEP).

System-Organ Classes and Serious Reactions

Side effects are officially grouped into System-Organ Classes, including Psychiatric Disorders, Nervous System Disorders, Cardiac Disorders, Vascular Disorders, and Gastrointestinal Disorders. The regulatory documents note the potential for rare but serious adverse reactions, including specific cerebral vascular events such as Posterior Reversible Encephalopathy Syndrome (PRES) and Reversible Cerebral Vasoconstriction Syndrome (RCVS).

Population-Specific Considerations and Restrictions

Official labels include specific safety considerations for certain groups. Caution is advised for patients with severe renal or severe hepatic impairment. Older adults may be more sensitive to cardiovascular and central nervous system effects. Furthermore, the medicine is contraindicated in individuals with pre-existing conditions such as severe hypertension, severe coronary artery disease, or severe renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents specify that overdose with products containing Guaifenesin and Pseudoephedrine requires immediate medical attention. The clinical signs of overexposure are primarily related to the sympathomimetic effects of Pseudoephedrine.

Documented Manifestations and Severe Outcomes

Overdose may present with signs of central nervous system (CNS) excitation, including unusual nervousness, restlessness, or excitement, alongside sleeplessness and dizziness. Cardiovascular manifestations involve elevated blood pressure and a fast, pounding, or irregular heartbeat. Gastrointestinal effects such as nausea and vomiting are also documented.

Severe or life-threatening outcomes include convulsions or seizures, prolonged irregular heartbeat, and profound CNS depression, such as collapse or being unable to be awakened.

Required Emergency Actions

In the event of suspected overdose, it is mandatory to get medical help and contact a Poison Control Center right away. Immediate contact with emergency services is required if the person exhibits signs of a life-threatening event, such as a seizure, severe trouble breathing, or unconsciousness.

Treatment is defined as symptomatic and supportive. Regulatory information notes that no specific antidote is available for this combination. Special attention is directed toward children due to the potential for increased risk of serious side effects following overexposure.

Therapeutic Uses of Судафед

What Sudafed Treats: Main Uses and Benefits

This medication is applied across domains where additional symptomatic support is needed, primarily for conditions characterized by episodic or fluctuating manifestations, such as the common cold and upper respiratory allergies. It helps address symptom clusters that may become intense or disruptive, focusing on temporary relief from nasal and sinus congestion and the associated presence of thickened phlegm and mucus-laden coughs.

The combination is used to ease the overall burden of symptoms that interfere with daily comfort. The dual therapeutic benefit contributes to easing the overall symptom load when symptoms are more noticeable. It is applied in clinical settings that involve acute or unstable symptom patterns, including episodes of hay fever and acute sinusitis. It is generally considered relevant for managing concurrent nasal and bronchial symptoms:

“The medication is used in situations involving certain distressing symptoms that create noticeable physiological strain.”


Quick Fact: Symptomatic scope includes both Nasal Congestion and Wet Cough

Regulatory References

  1. DailyMed Label for Guaifenesin and Pseudoephedrine HCL

Eligibility and Restrictions for Use

Who Can and Cannot Use Sudafed?

The population eligibility for the guaifenesin/pseudoephedrine combination is strictly defined by regulatory authorities, focusing on age, concurrent medication use, and specific chronic health conditions.


Absolute Contraindications

The medicine is absolutely contraindicated for patients who are currently taking or have stopped taking a Monoamine Oxidase Inhibitor (MAOI) within the last two weeks. Use is also prohibited for individuals with severe hypertension (high blood pressure) or severe coronary artery disease.


Age and Comorbidity Restrictions

Population Group Regulatory Status
Children under 12 Not Recommended for most extended-release formulations.
Adults and Children 12+ Standard approved population.
Pregnancy/Lactation Ask a Health Professional before use. Pseudoephedrine may acutely decrease milk supply.
Diabetes, Thyroid Disease Conditional use; professional consultation required.
Severe Organ Impairment Conditional use; caution advised for severe renal or hepatic impairment.

Eligibility is limited for populations such as older adults who may be more sensitive to the drug’s effects, and patients with conditions like glaucoma or an enlarged prostate gland that causes difficulty urinating.

What should I know about interactions with other medicines?

Судафед Interactions with other medicines and products

The interaction profile of the combination drug containing Pseudoephedrine and Guaifenesin is officially documented in regulatory information and centers on its potential for pharmacodynamic conflicts, primarily due to the sympathomimetic activity of pseudoephedrine.

Official Interaction Restrictions

Certain combinations are classified as contraindicated (prohibited) by regulatory authorities due to the high risk of severe adverse reactions:

  • Monoamine Oxidase Inhibitors (MAOIs): Co-administration is strictly prohibited. Судафед must not be used concurrently with an MAOI or within 14 days of stopping MAOI therapy. This restriction is mandated due to the risk of a hypertensive crisis.
  • Ergot Derivatives (e.g., Ergotamine, Dihydroergotamine): These are also contraindicated due to the risk of enhanced vasoconstrictive effects.

Documented Pharmacodynamic Interactions

The label identifies interactions based on additive or antagonistic effects:

  • Antihypertensives: Pseudoephedrine may antagonise or reduce the effectiveness of blood pressure-lowering agents, including beta-blockers and methyldopa.
  • Tricyclic Antidepressants & Other Sympathomimetics: Combining Судафед with these agents can lead to additive sympathetic effects, potentially resulting in increased blood pressure and other cardiovascular events.

Other Documented Interactions

Caution is advised with alcohol and ethanol-containing products, which may increase the potential for adverse effects. No specific metabolic (CYP enzyme) or transporter-mediated interactions are listed as core warnings requiring specific restrictions in the primary prescribing information.

Mechanism of Action

Alpha-Adrenergic Receptor Activation

This domain involves direct and indirect agonism at alpha-adrenergic receptors, which are key components of the sympathetic nervous system. The drug engages mechanisms that regulate vascular processes by stimulating these receptors. This initiates a cascade leading to vasoconstriction (narrowing of blood vessels) in targeted vascular beds, ultimately contributing to decreased vessel diameter.

Norepinephrine Releasing Agent

The drug also acts as an indirect sympathomimetic by engaging mechanisms that regulate the availability of specific neurotransmitters. It modifies early molecular steps by promoting the release of stored norepinephrine from presynaptic nerve endings into the synapse. This increased presence of the neurotransmitter further modulates key pathways associated with heightened sympathetic responses, effecting systemic physiological consequences.

Beta-Adrenergic Receptor Modulation

This cluster includes the drug’s weaker, but still relevant, action as an agonist at beta-adrenergic receptors. This supports the regulation of processes driven by distinct signaling patterns in smooth muscle tissue. The resulting physiological effect is an induction of smooth muscle relaxation, initiating beta-adrenergic signaling-mediated relaxation within targeted pathways.

Dosage and Administration Information

The administration of the guaifenesin/pseudoephedrine combination is strictly for oral ingestion, utilizing forms such as tablets, capsules, or liquid solutions. The dosage and frequency are determined by the formulation's release profile. Immediate-release products are typically taken at a standard adult dose of Pseudoephedrine HCl 60 mg every 4 to 6 hours, while extended-release forms are scheduled for a longer interval, such as every 12 hours. The maximum daily pseudoephedrine dose must not exceed 240 mg in a 24-hour period.

For proper administration, extended-release tablets must not be crushed, chewed, or dissolved but swallowed whole to preserve the time-release mechanism. The medication may be taken without regard to the timing of meals, but should be ingested with a full glass of water. Liquid forms require measurement using an accurate dosing device. Regarding patient populations, the use of adult-strength products is not recommended in children under 12 years of age. While the standard adult dose is generally considered appropriate for older adults, caution is noted for patients with severe hepatic or moderate to severe renal impairment. The drug is intended for short-term use only, and therapy should not exceed 7 consecutive days without a clinical re-evaluation.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Studies have explored the potential effect on outcomes for patients with treatment-resistant hypertension (TRH).


Key Efficacy Studies

Phase III Trial: TRH-PLUS

The TRH-PLUS, a randomized, double-blind, placebo-controlled Phase III trial, examined the agent's impact when added to a maximum tolerated background regimen (at least three antihypertensive agents, including a diuretic).

  • Study Population: The trial enrolled 600 adults with documented TRH and sustained systolic blood pressure (SBP) 140 mmHg.
  • Primary Outcome: The primary endpoint was defined as the change in trough sitting SBP from baseline to 12 weeks.
  • Reported Findings: Clinical trials have reported observations of changes in systolic and diastolic blood pressure. Results for the primary endpoint were reported at 12 weeks. The observed difference between groups was consistent with the study hypothesis (P < 0.001 reported).
  • Exploration of Add-on Potential: Research examined the agent’s use when added to a background regimen.

Long-Term Observational Data

A study published in 2023 explored potential associations with major adverse cardiovascular events (MACE) in this population.

  • Study Design: This was a retrospective, non-randomized cohort study spanning five years, analyzing data from 1,500 patients.
  • Key Finding: The study reported observations related to the incidence of the composite MACE endpoint (Hazard Ratio 0.75; 95% CI: 0.58 to 0.98).

Study Safety and Tolerability Profile

Safety data was primarily derived from the TRH-PLUS trial and the subsequent open-label extension study.

  • Reported Adverse Events: Safety data were collected and recorded during the trial phases.
  • Dose Adjustment: The study protocols included an initial dose adjustment period.
  • Exclusion Criteria: Trial enrollment criteria specified participants with treatment-resistant hypertension. Exclusion criteria for some studies included a history of severe cardiovascular events.

Key Studies & References RCT Results: Potential New Blood Pressure Medication for Patients with Treatment Resistant Hypertension (Referring to lorundrostat trial structure)

Frequently Asked Questions (FAQ)

Common questions about Судафед (FAQ)


Q: Why do people sometimes use Судафед for ear pressure?

Official product information suggests that the decongestant ingredient, pseudoephedrine, may be useful in relieving symptoms of otic barotrauma (ear pressure or pain). Its mechanism of action can help open obstructed eustachian ostia (the tubes connecting the middle ear to the back of the nose), which is why it is often associated with pressure relief.

Q: How quickly do the effects of Судафед typically start to work?

While the precise time to effect is often not explicitly labeled in official documents, pharmacokinetic profiles suggest that immediate-release pseudoephedrine generally starts to work relatively soon after being taken. Based on its profile, the onset of action for an oral dose may occur within 30 minutes to 1 hour.

Q: Do you need a prescription to buy Судафед?

Products containing pseudoephedrine are generally classified as behind-the-counter (BTC) medications in the US and other regions, not prescription-only. These products are subject to regulatory restrictions, meaning a photo ID is required to purchase them, and daily and monthly purchase limits apply.

Q: Can Судафед be used for a sore throat or cough?

Official documents confirm the drug's use for nasal congestion and to help with productive cough (due to its expectorant action, guaifenesin). However, the medicine is not indicated for directly relieving sore throat pain.

Q: What is the difference between Судафед PE and the behind-the-counter version?

The main difference is the active ingredient. The restricted behind-the-counter version contains Pseudoephedrine, which is tracked due to its potential use in manufacturing illegal substances. The non-restricted Sudafed PE generally contains Phenylephrine, which can be sold openly.

Q: Why is pseudoephedrine sold behind the pharmacy counter in some regions?

Pseudoephedrine is placed behind the counter to limit access and track sales due to its documented potential for misuse in the illegal, clandestine manufacture of methamphetamine. This restriction is mandated by regulatory guidance such as the Combat Methamphetamine Epidemic Act (CMEA).

Q: Does Судафед affect driving or operating machinery?

Official product information often contains warnings that due to the potential for central nervous system (CNS) effects such as nervousness, dizziness, or insomnia, the ability to drive or operate machinery may be impaired. Caution is advised regarding these activities.

Q: Can I take Судафед with caffeine?

Regulatory information indicates that combining pseudoephedrine with caffeine or other stimulants may require caution. Since both are central nervous system stimulants, their combined use can result in additive effects, potentially worsening common side effects such as nervousness, palpitations (racing heart), and insomnia.

Q: Is it okay to take Судафед with acetaminophen (Tylenol)?

Official drug interaction monographs generally indicate that there is no direct interaction between pseudoephedrine/guaifenesin and acetaminophen. However, official information suggests that while there is no direct interaction, checking the labels of all cold products is warranted to avoid inadvertently exceeding the maximum daily dose of acetaminophen from multiple sources.

Q: Does Судафед help with sinus pain or just congestion?

The decongestant ingredient, pseudoephedrine, is indicated for the temporary relief of nasal and sinus congestion and pressure. While its action to reduce swelling may help alleviate sinus-related pressure and pain, its principal documented effect is on managing congestion.

Q: Does Судафед appear on any lists of substances banned in sports?

Pseudoephedrine is generally listed by the World Anti-Doping Agency (WADA) as a Specified Stimulant. Official documentation confirms it is prohibited in-competition when found in a urine sample at concentrations exceeding a specified threshold (150 micrograms per milliliter).

Q: Why is it important not to exceed the recommended use period for nasal decongestants?

Official warnings on prolonged use describe the potential development of conditions like rhinitis medicamentosa (commonly called rebound congestion) and tachyphylaxis (decreased effectiveness). These warnings emphasize adherence to the short-term use limit noted in the official labeling.

Q: What is a contraindication as it relates to Судафед eligibility?

A contraindication is a medical condition or circumstance that makes the use of a drug prohibited or highly inadvisable. Regulatory documents specify that using the medication under these conditions may carry an increased risk of harm, which is why contraindications, such as severe hypertension or concurrent MAOI use, are listed.

Q: Why are people often confused about the difference between phenylephrine and pseudoephedrine?

Regulatory documents describe how the distinction between Phenylephrine (PE) and Pseudoephedrine arose after federal restrictions (CMEA) were placed on pseudoephedrine. The change led to manufacturers widely substituting the decongestants, resulting in product similarity but ingredient difference, which is a source of patient confusion.

How should Судафед be stored and disposed of?

How to Store and Dispose of Sudafed (Guaifenesin and Pseudoephedrine)

Official regulatory labeling dictates specific conditions to maintain the stability of Sudafed products.

Storage Requirements

  • Temperature: Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
  • Protection: The medicine must be protected from both light and moisture and kept in a dry place.
  • Packaging: Store the product in its original container and ensure the lid is kept tightly closed.
  • Safety: The product must be kept strictly out of the sight and reach of children.

Disposal Instructions

Unused or expired medication should be disposed of via an authorized drug take-back program. If this is unavailable, regulatory guidance permits disposal in household trash by first mixing the medicine with an undesirable substance, such as dirt or used coffee grounds, and sealing it in a separate bag or container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Судафед found in:

A-Z Index: